Rapid, sensitive mycoplasma detection for cell therapies, biologics, and biomanufacturing workflows, fully aligned with GMP and European Pharmacopoeia requirements (EP 10.1 chapter 2.6.7 Mycoplasmas).
Mycoplasma testing is a critical quality control step for biologics, vaccines, viral vectors, and ATMPs. These small bacteria can contaminate cell cultures without visible signs. BaseClear provides sensitive detection using validated workflows aligned with European Pharmacopoeia chapter 2.6.7 and GMP requirements.
GMP-compliant mycoplasma testing supports cell therapy and ATMP developers, biopharmaceutical companies, vaccine and viral vector manufacturers, CMOs, and translational research groups. It is commonly used for cell banks, production cell lines, raw materials, in-process samples, and final product release.
BaseClear uses validated NAT technology to detect a broad range of mycoplasma species in mammalian cell cultures. The workflow combines PCR-based detection with positive, negative, and internal controls under GMP-aligned laboratory conditions. This enables rapid, sensitive, and reliable testing that meets pharmacopeial requirements.
Clients receive a GMP-compliant report that can be directly used in regulatory documentation or quality systems.
Our specialists review your project, sample type, and regulatory requirements to define the right testing strategy. Where needed, matrix validation is assessed to confirm reliable assay performance.
You submit sample matrixes or samples such as supernatants, following our specifications.
Where needed, matrix suitability testing confirms that sample-specific inhibitors do not affect assay performance. Once suitability is established, samples are analyzed using a validated PCR-based method aligned with European Pharmacopoeia 2.6.7 and GxP requirements.
You receive a comprehensive analytical report suitable for quality documentation, regulatory submissions, and manufacturing release testing.
Schedule a free consultation with our experts to discuss your testing needs and regulatory
requirements. We’ll help design a compliant testing workflow for your project.
Mycoplasma contamination is the presence of bacteria from the Mollicutes class that lack a cell wall and frequently infect mammalian cell cultures. Because they are extremely small and do not cause visible turbidity in culture media, contamination often goes undetected without specialized testing. Mycoplasma infections can alter cellular metabolism, affect experimental outcomes, and compromise the safety of biopharmaceutical products.
Mycoplasma testing for biologics and cell-based products is required under pharmacopeial standards including European Pharmacopoeia chapter 2.6.7, USP <63>, and related GMP guidelines. These regulations specify validated detection methods and performance criteria for ensuring the absence of mycoplasma contamination.
Mycoplasma testing is typically required for master cell banks, working cell banks, production cell lines, raw materials of biological origin, in-process samples, and final drug products. Testing may also be required during routine cell culture maintenance or before initiating manufacturing campaigns.
Molecular detection methods can identify mycoplasma DNA within a few hours once testing begins. Rapid PCR-based workflows significantly reduce detection time compared with traditional culture-based methods, while maintaining the sensitivity required for regulated environments.
Validated molecular assays are designed to detect a wide spectrum of mycoplasma species known to contaminate cell cultures, including common contaminants such as Mycoplasma hyorhinis, Mycoplasma orale, and Mycoplasma pneumoniae, Mycoplasma arginini, Mycoplasma Synoviae, Mycoplasma fermentans, Archoleplasma laidlawii and Spiroplasma citri. Broad detection coverage is essential for reliable quality control.
Mycoplasma testing is essential for advanced therapy medicinal products (ATMPs) because contamination can directly impact patient safety and product efficacy. Regulatory authorities therefore require validated testing of cell banks and production materials before clinical use.
Schedule a free consultation with our experts to discuss your testing needs and regulatory requirements. We’ll help design a compliant testing workflow for your project.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
These cookies are needed for adding comments on this website.
Google Tag Manager simplifies the management of marketing tags on your website without code changes.
Service URL: business.safety.google (opens in a new window)
These cookies are used for managing login functionality on this website.
You can find more information in our Cookie statement and Cookie statement.